Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

Jean-Paul Viard; Jean-Claude Souberbielle; Ole Kirk; Joanne Reekie; Brygida Knysz; Marcelo Losso; Jose Gatell; Court Pedersen; Johannes R Bogner; Jens D Lundgren; Amanda Mocroft; Eurosida Study Group

doi:10.1097/qad.0b013e328347f6f7

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

Jean-Paul Viard, Jean-Claude Souberbielle, Ole Kirk, Joanne Reekie, Brygida Knysz, Marcelo Losso, Jose Gatell, Court Pedersen, Johannes R Bogner, Jens D Lundgren, Amanda Mocroft, Eurosida Study Group

LUKKET: Institut for Immunologi og Mikrobiologi

149 Citationer (Scopus)

Abstract

Background: We examined the association between vitamin D [25(OH)D] level and disease progression in HIV infection. Methods: Within the EuroSIDA study, 2000 persons were randomly selected for 25(OH)D measurement in stored plasma samples closest to study entry. 25(OH)D results were stratified into tertiles. Factors associated with 25(OH)D levels and associations of 25(OH) levels with subsequent risk of all-cause mortality, AIDS and non-AIDS events were analyzed. Results: Of 1985 persons with 25(OH)D levels available, 23.7% had 25(OH)D below 10, 65.3% between 10 and 30, and 11% above 30 ng/ml. At the time of 25(OH)D measurement, older persons, persons of black ethnic origin, living outside Southern Europe/Argentina, sampled during winter, and infected with HIV through nonhomosexual exposure were at higher odds of having low 25(OH)D levels, whereas persons receiving protease inhibitors were at lower odds. Compared to those in the lowest 25(OH)D tertile (<12 ng/ml), those in the middle (12-20) and higher (>20) tertiles had a significantly lower risk of clinical progression during subsequent follow-up. Adjusted incidence rate ratios for all-cause mortality were 0.68 (95% CI 0.47-0.99, P = 0.045) and 0.56 (95% CI 0.37-0.83, P = 0.0039), and for AIDS events were 0.58 (95% CI 0.39-0.87, P = 0.0086) and 0.61 (95% CI 0.40-0.93, P = 0.020), for the middle and higher tertiles, respectively. There was a similar, nonsignificant reduced incidence of non-AIDS events in the middle and higher tertiles. Conclusion: 25(OH)D deficiency was frequent in HIV-infected persons (83% on combined antiretroviral therapy), and was independently associated with a higher risk of mortality and AIDS events. Causality relationships should be examined, because of potential public health consequences.

Originalsprog	Engelsk
Tidsskrift	AIDS
Vol/bind	25
Udgave nummer	10
Sider (fra-til)	1305-1315
ISSN	0269-9370
DOI	https://doi.org/10.1097/qad.0b013e328347f6f7
Status	Udgivet - 19 jun. 2011

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1097/qad.0b013e328347f6f7

https://pdfs.journals.lww.com/aidsonline/2011/06190/Vitamin_D_and_clinical_disease_progression_in_HIV.8.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1543211601970;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzdN2ziiHhY6wPF9tfA80junkw0539YRhyhDXn5U9bZ7sk=;hash|rWXWlS11iw/ij0B8EEmw1w==

Citationsformater

@article{06e7842bdf534f44b395a31eb2095cfd,

title = "Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study",

abstract = "Background: We examined the association between vitamin D [25(OH)D] level and disease progression in HIV infection. Methods: Within the EuroSIDA study, 2000 persons were randomly selected for 25(OH)D measurement in stored plasma samples closest to study entry. 25(OH)D results were stratified into tertiles. Factors associated with 25(OH)D levels and associations of 25(OH) levels with subsequent risk of all-cause mortality, AIDS and non-AIDS events were analyzed. Results: Of 1985 persons with 25(OH)D levels available, 23.7% had 25(OH)D below 10, 65.3% between 10 and 30, and 11% above 30 ng/ml. At the time of 25(OH)D measurement, older persons, persons of black ethnic origin, living outside Southern Europe/Argentina, sampled during winter, and infected with HIV through nonhomosexual exposure were at higher odds of having low 25(OH)D levels, whereas persons receiving protease inhibitors were at lower odds. Compared to those in the lowest 25(OH)D tertile (<12 ng/ml), those in the middle (12-20) and higher (>20) tertiles had a significantly lower risk of clinical progression during subsequent follow-up. Adjusted incidence rate ratios for all-cause mortality were 0.68 (95% CI 0.47-0.99, P = 0.045) and 0.56 (95% CI 0.37-0.83, P = 0.0039), and for AIDS events were 0.58 (95% CI 0.39-0.87, P = 0.0086) and 0.61 (95% CI 0.40-0.93, P = 0.020), for the middle and higher tertiles, respectively. There was a similar, nonsignificant reduced incidence of non-AIDS events in the middle and higher tertiles. Conclusion: 25(OH)D deficiency was frequent in HIV-infected persons (83% on combined antiretroviral therapy), and was independently associated with a higher risk of mortality and AIDS events. Causality relationships should be examined, because of potential public health consequences.",

author = "Jean-Paul Viard and Jean-Claude Souberbielle and Ole Kirk and Joanne Reekie and Brygida Knysz and Marcelo Losso and Jose Gatell and Court Pedersen and Bogner, {Johannes R} and Lundgren, {Jens D} and Amanda Mocroft and {Eurosida Study Group}",

year = "2011",

month = jun,

day = "19",

doi = "10.1097/qad.0b013e328347f6f7",

language = "English",

volume = "25",

pages = "1305--1315",

journal = "AIDS, Supplement",

issn = "1350-2840",

publisher = "Lippincott Williams & Wilkins",

number = "10",

}

TY - JOUR

T1 - Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

AU - Viard, Jean-Paul

AU - Souberbielle, Jean-Claude

AU - Kirk, Ole

AU - Reekie, Joanne

AU - Knysz, Brygida

AU - Losso, Marcelo

AU - Gatell, Jose

AU - Pedersen, Court

AU - Bogner, Johannes R

AU - Lundgren, Jens D

AU - Mocroft, Amanda

AU - Eurosida Study Group

PY - 2011/6/19

Y1 - 2011/6/19

N2 - Background: We examined the association between vitamin D [25(OH)D] level and disease progression in HIV infection. Methods: Within the EuroSIDA study, 2000 persons were randomly selected for 25(OH)D measurement in stored plasma samples closest to study entry. 25(OH)D results were stratified into tertiles. Factors associated with 25(OH)D levels and associations of 25(OH) levels with subsequent risk of all-cause mortality, AIDS and non-AIDS events were analyzed. Results: Of 1985 persons with 25(OH)D levels available, 23.7% had 25(OH)D below 10, 65.3% between 10 and 30, and 11% above 30 ng/ml. At the time of 25(OH)D measurement, older persons, persons of black ethnic origin, living outside Southern Europe/Argentina, sampled during winter, and infected with HIV through nonhomosexual exposure were at higher odds of having low 25(OH)D levels, whereas persons receiving protease inhibitors were at lower odds. Compared to those in the lowest 25(OH)D tertile (<12 ng/ml), those in the middle (12-20) and higher (>20) tertiles had a significantly lower risk of clinical progression during subsequent follow-up. Adjusted incidence rate ratios for all-cause mortality were 0.68 (95% CI 0.47-0.99, P = 0.045) and 0.56 (95% CI 0.37-0.83, P = 0.0039), and for AIDS events were 0.58 (95% CI 0.39-0.87, P = 0.0086) and 0.61 (95% CI 0.40-0.93, P = 0.020), for the middle and higher tertiles, respectively. There was a similar, nonsignificant reduced incidence of non-AIDS events in the middle and higher tertiles. Conclusion: 25(OH)D deficiency was frequent in HIV-infected persons (83% on combined antiretroviral therapy), and was independently associated with a higher risk of mortality and AIDS events. Causality relationships should be examined, because of potential public health consequences.

AB - Background: We examined the association between vitamin D [25(OH)D] level and disease progression in HIV infection. Methods: Within the EuroSIDA study, 2000 persons were randomly selected for 25(OH)D measurement in stored plasma samples closest to study entry. 25(OH)D results were stratified into tertiles. Factors associated with 25(OH)D levels and associations of 25(OH) levels with subsequent risk of all-cause mortality, AIDS and non-AIDS events were analyzed. Results: Of 1985 persons with 25(OH)D levels available, 23.7% had 25(OH)D below 10, 65.3% between 10 and 30, and 11% above 30 ng/ml. At the time of 25(OH)D measurement, older persons, persons of black ethnic origin, living outside Southern Europe/Argentina, sampled during winter, and infected with HIV through nonhomosexual exposure were at higher odds of having low 25(OH)D levels, whereas persons receiving protease inhibitors were at lower odds. Compared to those in the lowest 25(OH)D tertile (<12 ng/ml), those in the middle (12-20) and higher (>20) tertiles had a significantly lower risk of clinical progression during subsequent follow-up. Adjusted incidence rate ratios for all-cause mortality were 0.68 (95% CI 0.47-0.99, P = 0.045) and 0.56 (95% CI 0.37-0.83, P = 0.0039), and for AIDS events were 0.58 (95% CI 0.39-0.87, P = 0.0086) and 0.61 (95% CI 0.40-0.93, P = 0.020), for the middle and higher tertiles, respectively. There was a similar, nonsignificant reduced incidence of non-AIDS events in the middle and higher tertiles. Conclusion: 25(OH)D deficiency was frequent in HIV-infected persons (83% on combined antiretroviral therapy), and was independently associated with a higher risk of mortality and AIDS events. Causality relationships should be examined, because of potential public health consequences.

U2 - 10.1097/qad.0b013e328347f6f7

DO - 10.1097/qad.0b013e328347f6f7

M3 - Journal article

C2 - 21522006

SN - 1350-2840

VL - 25

SP - 1305

EP - 1315

JO - AIDS, Supplement

JF - AIDS, Supplement

IS - 10

ER -

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater